Baricitinib, an oral JAK inhibitor that reversibly inhibits JAK1 and JAK2 and moderately inhibits TYK2 has been shown to reduce pruritus in AD patients [85,86]. The gene discussed is JAK2; the disease is Alzheimer disease.